Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer-Reference-Cited by-同舟云学术

Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer

Published:2019-07-18 Issue:10 Volume:36 Page:927-938
ISSN:1170-229X
Container-title:Drugs & Aging
language:en
Short-container-title:Drugs Aging

Author:

van Holstein Yara^ORCID,Kapiteijn Ellen,Bastiaannet Esther,van den Bos Frederiek,Portielje Johanneke,de Glas Nienke A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Geriatrics and Gerontology

Link

http://link.springer.com/content/pdf/10.1007/s40266-019-00697-2.pdf

Reference67 articles.

1. Kankerregistratie, N. Cijfers over kanker. 2019; Incidentiecijfers melanoom, longkanker, kanker urinewegen]. www.cijfersoverkanker.nl . Accessed 5 Jul 2019.

2. Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–603.

3. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65.

4. de Glas NA, Kiderlen M, Vandenbroucke JP, et al. Performing survival analyses in the presence of competing risks: a clinical example in older breast cancer patients. J Natl Cancer Inst. 2016;108(5):p.djv366.

5. Wildiers H, Mauer M, Pallis A, et al. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer: alliance for Clinical Trials in Oncology-International Society of Geriatric Oncology position article. J Clin Oncol. 2013;31(29):3711–8.

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response;Pharmacology & Therapeutics;2024-10

2. Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study;Cancer Letters;2024-08

3. Immunotherapy use in older adults with cancer with frailty: A young SIOG review paper;Journal of Geriatric Oncology;2024-05

4. Toxicity in Older Patients with Cancer Receiving Immunotherapy: An Observational Study;Drugs & Aging;2024-05

5. Occurrence of Fatal Tubulopathy in an Old, Fit Patient Receiving Nivolumab and Ipilimumab for Metastatic Melanoma: A Case Report;Case Reports in Oncology;2024-02-14